Otonomy, Inc. (OTIC)
OTICPrice: $0.01
Fair Value: 🔒
🔒score
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustain... more
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United Stat... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David M. Maggio |
| IPO Date | 2014-08-13 | CAGR | — |
| Employees | 51 | Website | www.otonomy.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
OTIC chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.49M | P/E Ratio | -0.14 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | -0.01 | P/FCF Ratio | — |
| EPS | $-0.06 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | -1.96% |
| Operating Margin | -397% | Profit Margin | -402.6% |
| ROE | 0.09% | ROA | -0.53% |
| ROCE | -0.6% | Current Ratio | 6.52 |
| Quick Ratio | 6.52 | Cash Ratio | 6.28 |
| Debt/Equity | -0.03 | Interest Coverage | -31.04 |
| Altman Z Score | -16.93 | Piotroski Score | 2 |